Some great obsevations - thanks both! (not sure why the link to @enkayess's post didn't work)
What I take from this and the pathway of other ALS treatments seeking regulatory approval (enkayess mentioned this as well) is that drugs that are shown to be safe (even with some minor AE's) are progressing to market extremely quickly, even when the efficacy produced is limited or still to be proved.
If true, MPL may translate rapidly from clinical trials to market, as it is a well known drug with an established safety profile.
My guess is that signs of efficacy and no or very minor AE's from the current trial will see us move to almost immediately into a Phase 2 trial and the partners will be circling.
Cheers
Densy
Ann: First Patient Dosed in MND Phase 1/2 Trial, page-157
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.1M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 22.0¢ | $89.24K | 403.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 142257 | 3 |
View Market Depth
| Last trade - 15.52pm 17/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |